Ohio Medicaid and tirzepatide
Zepbound for weight loss: not confirmed. The October 2026 Unified Preferred Drug List does not mention Zepbound, and absence is not a no. No state document naming Zepbound's coverage was found. The only mention read is a safety note in a 2026 DUR digest. Mounjaro for weight loss: no. Non-preferred in the diabetes class. Requires A1C above 7 percent before starting and a trial of Ozempic or a documented reason it cannot be used.; for type 2 diabetes Ohio Medicaid must cover it. Read from Ohio Department of Medicaid documents Nov 6, 2026.
In 2025 Ohio Medicaid paid for 28,185 tirzepatide prescriptions (Mounjaro, Zepbound), 6.6% of its GLP-1 prescriptions and 20th of the 50 states and DC. It reimbursed $26.8 million before rebates, $951 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 25,193 | $23.6 million | $938 |
| Zepbound | 2,992 | $3.2 million | $1,058 |
Ohio plans and prescribing rules
State of Ohio employee health plan (Ohio DAS). Ohio's state employee benefits plan stopped covering GLP-1s for weight loss, such as Wegovy and Zepbound, on July 1, 2025. GLP-1s for diabetes, such as Ozempic and Mounjaro, stay covered.
Tirzepatide in the states around Ohio
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Ohio | 17 | $69/moWellmedr | 28,185 | Medicaid Zepbound: Not confirmed |
| Indiana | 17 | $69/moWellmedr | 19,161 | Medicaid Zepbound: No |
| Kentucky | 17 | $69/moWellmedr | 66,258 | Medicaid Zepbound: No |
| Michigan | 17 | $69/moWellmedr | 228,461 | Medicaid Zepbound: Yes |
| Pennsylvania | 17 | $69/moWellmedr | 243,243 | Medicaid Zepbound: No |
| West Virginia | 16 | $69/moWellmedr | 2,257 | Medicaid Zepbound: No |



